Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

04.06.2022 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, presented today new and updated results from the CARTITUDE ...

Related Keywords

China ,Japan ,United States ,New Jersey ,Chinese ,American ,Hemophagocytic Lymphohistiocytosis ,Saadz Usmani ,Ying Huang ,Janssen Biotech Inc ,Exchange Commission On ,American Society Of Clinical Oncology ,Linkedin ,Twitter ,Myeloma Service ,Chinese Center ,European Commission For The Treatment Of Patients ,American Society Of Hematology ,American Society Of Clinical Oncology Annual Meeting ,Legend Biotech Corporation ,Drug Evaluation Of National Medical Products Administration ,Community Register Of Orphan Medicinal Products ,American Cancer Society ,Drug Administration ,European Commission ,Medicinal Devices Agency ,European Medicines Agency ,Biotech Inc ,Memorial Sloan Kettering Cancer Center ,Confident Interval ,Annual Meeting ,Reinforce Potential ,Executive Officer ,Legend Biotech ,Janssen Biotech ,Breakthrough Therapy Designation ,Drug Designation ,Orphan Medicinal Products ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Nerve Palsies ,Recurrent Cytopenias ,Igg Hypersensitivity Reactions ,Use Machines ,Prescribing Information ,Boxed Warning ,Private Securities Litigation Reform Act ,Medicines Agency ,Drug Evaluation ,National Medical Products Administration ,Investigational New Drug ,Annual Report ,Exchange Commission ,Clinical Oncology Annual ,Adult Patients ,Refractory Multiple ,Granted Conditional Approval ,Community Register ,Orphan Medicinal ,Accessed May ,Statistics About Multiple Myeloma ,